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Results: There were 603 patients who underwent saphenous vein graft PCI; 411 were
event-free at the time of clopidogrel cessation and comprised the study cohort. The
incidence rate ratio (95% CI) for death or myocardial infarction in the 0-90 day interval
compared with the 91-365 day interval was 2.58 (1.64-4.07). Similar results were
observed over a broad range of clopidogrel treatment durations (6 months, 6 months- 1
year, 1-2 years, or2 years). The results were also consistent across subgroups including
gender, stent type, stent diameter, study period, and diabetes status. The risk-adjusted
instantaneous incidence rate for death or MI was greatest early after clopidogrel cessation,
regardless of clopidogrel duration (see figure).
Conclusions: A clustering of events was observed in the initial 0-90 days after
clopidogrel cessation in all treatment durations of clopidogrel investigated after SVG PCI.
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Background: Evidence on the use of newer antiplatelet agents and their cost implications
remains scarce. Previous research has shown a shorter average hospital length of stay for
prasugrel-treated patients compared to clopidogrel-treated patients. We analyzed a large
geographically diverse database from the US and compared cost of hospitalization for
patients with acute coronary syndrome (ACS) who have undergone percutaneous
coronary intervention (PCI) and who received either clopidogrel or prasugrel.
Methods: Using a large representative US database maintained by PREMIER, we
analyzed patient characteristics and total hospitalization costs during the index (first)
hospitalization among ACS-PCI patients treated with clopidogrel or prasugrel between
July 2009 and June 2011. Analysis included patients treated with prasugrel who were
on-label and clopidogrel-treated patients who would have been eligible for prasugrel
treatment per the label. Observed costs were analyzed unadjusted and adjusted for
baseline differences using a generalized linear model with a gamma distribution and log
link function with propensity score stratification.
Results: Data were available for 75,315 patients who received clopidogrel and 9,483
patients who received prasugrel during their hospitalization. The observed mean hospi-
talization costs (SD) for clopidogrel and prasugrel, respectively, were $17,519 ($2,548)
and $17,136 ($2,562). Mean costs for clopidogrel and prasugrel recipients, respectively,
were $16,937 ($2,162) and $16,664 ($2,137) for STEMI, $17,926 ($2,747) and $17,511
($2,849) for NSTEMI, and $17,900 ($2,665) and $17,393 ($2,676) for UA (all
comparisons, P0.001). The adjusted results showed prasugrel-treated patients cost as
much as $882 less than clopidogrel-treated patients (P0.001) during the index hospital
stay.
Conclusions: Prasugrel-treated patients used fewer health care resources compared to
clopidogrel-treated patients during the index hospital stay, as measured by hospital costs.
Similar results were obtained after adjusting for patient demographics and clinical
characteristics. The potential for unmeasured confounder bias is a limitation in this
real-world observational research.
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Background: The use of any thienopyridine within 5 days before enrollment was an
exclusion criteria for the TRITON TIMI 38 Trial. There are no clinical data concerning
the safety of switching from clopidogrel to prasugrel in patients undergoing coronary
stenting. However, in the daily activity, clinicians face the decision of switching high-risk
patients from clopidogrel to prasugrel. We sought to evaluate in-hospital events in
high-risk patients undergoing coronary stent implantation and prasugrel therapy with
(SWITCH group) or without (NAÏVE group) previous clopidogrel therapy.
Methods: From March 2010 to December 2011 a total of 718 patients aged 68  11
years (32% older than 75 years) underwent stent implantation and received prasugrel
therapy (77 with a 60 mg loading dose). Of these, 370 (51%) patients have received
clopidogrel before prasugrel therapy: high residual platelet reactivity (HRPR) on clopi-
dogrel had been documented in 258 patients by LTA (ADP 10).
Results: Seventy-seven SWITCH group patients received a 60 mg prasugrel loading
dose. NAÏVE group patients were more likely to have ST-elevation myocardial infarction
(60% vs 15%) and a younger age (mean age 66 vs 70 years). There was no difference in
BARC in-hospital bleeding (4.1% vs 4.9%; p0.578) between the SWITCH and NAÏVE
groups as well as in mortality, acute stent thrombosis, reinfarction and stroke rates. At
multivariable analysis, independent predictors of in-hospital bleeding were female gender
(OR 3.53 [1.34-9.35], p0.011) and diabetes (OR 3.22 [1.23-8.37], p0.017), but
switching therapy did not. This result was confirmed after switching propensity score
adjustment (c-statistic 0.77; Hosmer-Lemeshow test p 860). In patients with HRPR on
clopidogrel, prasugrel decreased platelet aggregation from 7211% to 4316%
(p0.001).
Conclusions: Switching from clopidogrel to prasugrel in high-risk patients undergoing
coronary stent implantation seems to be not associated with any short term major concerns
regarding prasugrel safety and efficacy.
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Background: Paraoxonase (PON) is a high-density-lipoprotein (HDL) associated en-
zyme with antioxidative and anti-atherogenic property. Its function is associated with
coronary artery disease and its activity genetically controlled. We evaluated whether
genetic variation of PON-1 is associated with clinical outcome in a large cohort of Korean
patients with drug-eluting stents implantation.
Methods: A total of 1676 patients with drug-eluting stent implantation were enrolled in
the prospective CROSS-VERIFY cohort from June 2006 to June 2010. We genotyped the
PON1-Q192R gene, measured clopidogrel on-treatment platelet reactivity (OPR), and
analyzed lipid profiles. The primary endpoint was the composite of cardiac death,
myocardial infarction, and stent thrombosis at 12 months.
Results: PON-1 genotyping data were available in 1336 patients. Since the Q-allele is
associated with decreased PON-activity, we analyzed the outcome between patients with
QQ/QR (815 patients, 61%) and those with RR-genotype (521 patients, 39%). After
adjustment for common cardiac risk factors, the QQ/QR-genotype was an independent
predictor of the primary thrombotic endpoint with an 11-fold increased risk (HR 11.5,
95% CI: 1.54-86.6), but not repeat revascularization (HR 1.13, 95% CI: 0.78-1.62). The
QQ/QR-genotype was not associated with OPR (QQ/QR: 23186 PRU vs. RR 23682
PRU, p0.342) but higher small-dense LDL levels (1.200.12 mg/dL vs. 0.760.15
mg/dL, p0.027). The increased risk of thrombotic outcomes was more profound in acute
coronary syndrome (ACS) patients compared with non-ACS patients.
Conclusions: PON1 Q-allele is an independent predictor of worse cardiovascular
outcome independent of platelet function and is associated with significantly higher levels
of small dense LDL-C. PON-1 genotype may serve as a novel genetic risk factor for
adverse events after PCI.
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Antithrombin and Antiplatelet Agents B213
P
O
ST
E
R
S
